Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
 |
New Vision (Kampala) - October 21, 2004
Abubaker Mukose
The drug guards against the spread of the virus.
Dr. Ann Kolokathis, an infectious diseases specialist from the Pfizer Global Pharmaceuticals (PGP), on Tuesday said trials would begin in November.
"The CCR5 inhibits the virus from entering the cell receptor, so it protects infection of other cells in HIV/AIDS patients and they can live a little longer," Kolokathis said during a tour of Jinja Hospital.
She was part of a Pfizer Diflucan Partnership delegation, a programme that provides free anti-fungal medicine, Diflucan, for HIV/AIDS patients with opportunistic infections like cryptococcal meningitis and esophageal candidiasis.
Pfizer provides Diflucan to 987 sites in the 25 countries worst hit by HIV/AIDS.
Kolokathis was accompanied by PGP Europe chief Dr. Jack Watters.
041021
NV041035
Copyright © 2004 - The New Vision. All articles are republished on AEGIS by permission. Material may not be redistributed, posted to any other location, published or used for broadcast without written authorization from Managing Director/Editor-in-chief, The New Vision, P.O. Box 9815, Kampala - Uganda, Tel/fax: 256-41-235221, E-mail: wpike@newvision.co.ug.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .